Aquestive Therapeutics, Inc. (AQST), a pharmaceutical company, Wednesday announced that it has appointed Matthew Greenhawt, as its Chief Medical Officer.
According to the company, Greenhawt is an internationally recognized expert in allergy and immunology with particular expertise in food allergy, anaphylaxis, patient-centered care, and health services and health policy research.
He takes over from Gary Slatko who was serving as the interim Chief Medical Officer.
Most recently, Greenhawt served as Chief Medical Officer of the Asthma and Allergy Foundation of America. Prior to this, he was the Professor of Pediatrics at Childrens Hospital Colorado and the University of Colorado School of Medicine.
In pre-market, AQST shares were trading at $3.90, up 0.52% on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.